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The spectrum of bone disease in end-stage renal failure—An evolving
disorder. We have assessed the bone histology in 259 chronic dialysis
patients, all of whom were in the same dialysis program. All patients
had bone biopsies with quantitative histomorphometry, intact parathy-
roid hormone (PTH) measurements, basal and deferoxamine stimulated
serum aluminum levels. Results demonstrate the increased incidence of
the recently described aplastic bone lesion, particularly in patients
treated with peritoneal dialysis (PD). Aluminum-related bone disease is
much less common than previously described, perhaps in relation to the
declining use of aluminum as a phosphate binder. A different pattern of
bone lesions is seen in PD as compared with hemodialysis (HD), with
low turnover disorders comprising 66% of the lesions seen in PD and
high turnover lesions accounting for 62% of the bone histologic findings
in HD. The difference in these patterns may relate to alterations in PTH
levels, as mean PTH levels in HD patients were 2-1/2 times the levels
found in PD patients (P < 0.0005), while older age, higher prevalence of
diabetes and a shorter duration of dialysis may also have contributed to
the findings in the PD patients, We suggest that PD, perhaps by
maintaining calcium at higher levels, may more effectively suppress the
parathyroid gland.
Renal osteodystrophy (ROD) continues to be a therapeutic
dilemma for the practicing nephrologist. The mechanisms for its
development are both multifactorial and controversial. Not
surprisingly, the most appropriate treatments also are conjec-
tural [1]. Analyses are further complicated by changes in the
treatment for end-stage renal disease over recent years, includ-
ing the greater use of PD, which may have influenced the
pattern of disease.
Recently, a low turnover bone condition without an increase
in osteoid volume has been described in patients with chronic
renal failure. Originally seen in conjunction with excess alumi-
num, this lesion is now found to occur in the absence of
aluminum [21. Its cause is not entirely clear at this time.
In this paper we report the prevalence of the various bone
lesions in 259 chronic dialysis patients. Since nearly equal
populations underwent PD (N = 142) and HD (N 117), we
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were able to assess the influence of the different dialysis
modalities on the bone histology. We also describe the relation-
ship of the bone histology to bone aluminum levels and the
serum aluminum and PTH levels.
In addition to the material to be presented in this report a
large amount of clinical and laboratory data will be presented in
other reports on this study.
Methods
Four hundred and forty-five patients in or entering the
dialysis programs in three Toronto area hospitals between
January 1987 and June 1988 were assessed serially for a
minimum of one year of follow-up. A variety of clinical and
laboratory data, described elsewhere [31, were collected in
addition to intact PTH, fasting and deferoxamine-stimulated
aluminum levels and bone biopsy. By the end of the study
period 268 patients had completed follow-up and all of the
special investigations. Of these 268 patients, 248 were selected
randomly and 20 were referred because of clinical findings
suggestive of bone disease. The 20 referred subjects were from
the same programs in Toronto as the other patients. They met
all criteria for study entry and would have been invited to
participate even if they had not been referred. The distribution
of bone lesions in these 20 patients did not skew the results, and
this is specifically delineated in the Results section. Nine
subjects had inadequate bone biopsies or their samples for
aluminum or PTH measurements were lost, so that complete
data were obtained on 259 subjects. Demographic data depicted
in Table 1 have been previously reported [3].
Of the 177 patients who were excluded, two-thirds died or
were transplanted during the study period. A smaller number
failed to complete studies for a variety of personal and medical
reasons. Clinical and other risk factors for renal osteodystrophy
were not different for these patients from those who completed
the study. Overall, only 20 patients (out of a total of 288), who
were eligible and asked to participate, refused.
All the study patients gave informed consent after full expla-
nation of the details, procedures, and potential risks of the
study. The protocol and consent form were approved by the
institutional review board of the University of Toronto.
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Table 1. Patient demographics at the time of bone biopsy
Pentoneal Hemodialysis P value
Male/female 79/63 78/39 0.093
Age at biopsy years 60 12 52 1.4 < 0.0005
Dialysis duration years 3.2 0.3 5.3 0.5 <0.0005
Cumulative Al (OH)3 1.9 0.3 4.3 0.5 < 0.0005
dose since dialysis kg
On CaCo3 only % 38 17 <0.0005
Diabetes mellitus % 30 19 < 0.05
Failed renal allograft % 10 21 < 0.02
Parathyroidectomy 4 6 NS
Data are expressed as ratio, mean (±sE) or %, and are adapted from
reference 3.
Biopsies were obtained from each subject after one year of
monitoring of clinical and laboratory data, which included
intact PTH, aluminum and deferoxamine stimulation [3]. They
were processed as previously described [4, 5]. The recently
described tetracycline labeling technique [6] was used in which
single oral doses of tetracycline and declomycin are given two
to three weeks and three to five days, respectively, before the
biopsy.
Biopsies were classified according to previous criteria [4, 7]
(Table 2). The areas of osteoid and fibrosis were used to
distinguish most lesions, while bone formation rate was used to
separate aplastic patients from mild subjects. Normal data for
static parameters are from 79 adults, age 20 to 80, equally
distributed among the six decades and by sex. Of these normal
subjects, 42 had dynamic data determined. Bone histologic data
are reported using standardized nomenclature and definitions
[81. The five groups were defined quantitatively as: mild, with
an increase in osteoid covered bone surfaces; osteomalacia,
with an increase in osteoid area; osteitis fibrosa, with an
increase in area of peritrabecular fibrosis; mixed uremic os-
teodystrophy, with an increase in both fibrosis and osteoid; and
aplastic disorder, with features similar to the mild disorder plus
a low bone formation. Bone formation generally was high in
patients with osteitis fibrosa and mixed uremic osteodystrophy,
normal in the mild group, and low in the patients with osteo-
malacia or the aplastic lesion, but was only used as a criterion
to distinguish the mild group from the aplastic disorder. Some
authorities prefer to use osteoid width instead of osteoid
volume to define osteomalacia. In this study this distinction is
of importance only in differentiating the aplastic from the
osteomalacic groups. The aplastic subjects had an osteoid width
of 7.0 2.7 j while the osteomalacic patients had an osteoid
width of 18.8 3.8 s (mean SD). The value for the aplastic
subjects is the same as normal subjects. Using a cutoff of 14 i
one aplastic subject would exceed this value and one osteoma-
lacic would fall below it. As both of these subjects had >25%
surface aluminum, switching these two subjects would not
affect any of our results or conclusions.
Parathyroid hormone (PTH) and aluminum assays were per-
formed according to published techniques [9, 10]. The alumi-
num stimulation test, using deferoxamine, was also carried out
as previously described [11].
During the period these studies were being conducted pa-
tients were treated with conventional dialysis fluids containing
calcium at a concentration of 3.25 mEq/liter. Phosphate control
Table 2. Histologic classification of renal osteodystrophy
Area of Area of
fibrosis osteoid Bone formation rate
% of tissue % of total 1wn2/mm2 tissue
Lesion area bone area area/day
Mild <0.5% < 15% > 108
Osteitis fibrosa > 0.5% < 15% X
Mixed > 0.5% > 15% X
Osteomalacia <0.5% > 15% X
Aplastic <0.5% < 15% < 108
Normal range 0 1—7% 108—500
X is not a diagnostic criterion
emphasized diet with aluminum hydroxide being the primary
phosphate binder early in the study, while late in the study
calcium carbonate predominated. No attempt was made by the
investigators to control the doses of these or other usually
prescribed agents. Dosages were determined by several prac-
ticing nephrologists according to accepted criteria. Plasma total
calcium and phosphate were monitored monthly. Therapeutic
goals for these tests were as follows: calcium, 2.2 to 2.6
mmollliter; phosphate, 1.3 to 1.8 mmollliter. Calcium was
maintained with calcium carbonate, with calcitriol added as
needed. Only 33 (12.7%) patients actually received calcitriol, 24
at a dose of 0.25 j.g daily, four at a dose of 0.50 g daily, and
only one patient at a dose exceeding 1.0 g daily. Calcitriol
therapy was given to patients in all histologic groups and
distributed equally between HD (N = 13) and PD (N = 20).
Only 10 of these subjects had had a parathyroidectomy prior to
the study period. Patients with prior parathyroidectomy were
equally divided between normal/high turnover (mild, fibrotic,
mixed uremic osteodystrophy) and low turnover (aplastic,
osteomalacic) lesions. Aluminum concentration was monitored
quarterly in both blood and dialysate and was <10 g/1iter in
both HD and PD fluids. Magnesium concentration in the
dialysate was 1.5 mEqlliter in PD and 1.0 in HD.
Statistics included the chi square test, analysis of variance,
(-tests, regression, Tukey's method for multiple comparisons as
reported by Kramer [12] and Fisher's Exact test (STATXACT
software [13] gives an asymptotic approximation in large sam-
ple sizes). The SAS software system [14] was used for most
analyses. For subgroup analyses when the same test is applied
to a number of different groups, spurious significances may be
seen because of the number of tests being done. A conservative
rule is to multiply P values by 5 when the same test is done for
all five groups of bone disease assessed. This rule has been
followed in P values obtained from 1-tests on data presented in
Tables 3 and 6. Data are reported as mean standard error.
Results
The distribution of lesions and quantitative histomorphomet-
nc results are described in Table 3 for the total population. Two
points are particularly noteworthy. First, osteomalacia, for-
merly a common lesion, was the least common pattern, making
up only 4% of the total. Second, the recently described aplastic
disorder accounted for half (49.4%) of the bone lesions seen.
Other findings of interest are that bone surface aluminum,
which was increased in all groups, was markedly higher in the
438 Sherrard et a!: Current status of renal osteodystrophy
Table 3. Quantitative histomorphometry
Lesion N
Mineral
Total Osteoid Fibrosis Surface Osteoid Eroded apposition
bone area area area aluminum surface surface rate Bone formation rate
Mild 45 21.5 0.8 5.8 0.5 0.2 0.2 19.2 3.0 45.0 2.5 10.3 0.7 0.8 0.03 247 21"
Osteitjs fibrosa 57 25.1 1.0 9.0 0.4 2.2 0.3 15.8 2.2 56.9 1.6 16.6 0.9 0.9 0.3 694 55"
Mixed 18 31.7 3.0 23.7 2.0 2.5 0.5 18.6 4.4 79.5 2.5 11.2 1.5 0.8 0.02 632.6 115"
Osteomalacia 11 24.4 2.6 23.3 4.2 0.07 0.04 53.9 8.5 77.8 7.4 2.7 0.5 0,3 0.01 33.1 18.4"
Aplastic 128 19.8 0.5 4.9 0.3 0.02 0.005 18.5 1.8 42.6 1.8 6.5 0.3 0.5 0.03 26.4 2.6"
Normala 79 21.3 0.6 3.5 0.2 0 0 20.3 0.2 5.5 0.3 0.65 0.02 307 17
Definition of terms is from reference [81. Total bone area is the percentage of tissue area that is occupied by mineralized bone and osteoid.
Osteoid area is the percentage of bone that is unmineralized osteoid. Fibrosis area is the percentage of tissue area occupied by fibrous tissue.
Surface aluminum is the percentage of cancellous bone surface staining for aluminum. Osteoid and eroded surface are also the percentage of
cancellous bone surface covered with osteoid or eroded by osteoclasts, respectively. Mineral apposition rate is the average width of mineral
deposited at bone forming sites per day. Bone formation rate is the area of mineral in jm2 deposited per mm2 of tissue area per day (see Table
1).
a 79 normal subjects had static measurements; 42 had dynamic measurements (mineral apposition rate and bone formation rate)b Mild> OM, @ P = 0.001; mixed > OM, aplastic @ P = 0.001 by Wilcoxon rank sum test [14]
OM> all other groups @ P> 0.001
Table 4. Surface bone aluminum in peritoneal dialysis and hemodialysis patients
Histologic
groups
Peritoneal Hemodialysis 1-test
PN Surface N Surface
Mild 30 14.4 3.6 15 28.7 4,5 O.lO'
Osteitis fibrosa 13 14.7 5.3 44 16.2 2.4 0.78
Mixed 5 4.6 5.7 13 24 5.2a 0025b
Osteomalacia 8 47.4 10.4 3 71.3 9.6 0.22
Aplastic 86 13.1 1.8 42 29.4 3,3a 00005b
Total 142 15.0 1.6 117 24.8 1.9 0.0001
a Significant by t-test as notedb P values multiplied by 5 (see Methods)
osteomalacic group. Finally, bone formation rates were ele-
vated in both the patients with osteitis fibrosa and mixed uremic
osteodystrophy, but depressed in osteomalacic and aplastic
groups (not surprising in the latter, since this is how they were
defined). Of the 20 referred patients one was excluded for
incomplete data. The remaining 19 included 13 PD and six HD
patients. They were distributed throughout the various histo-
logic groups as follows: five aplastic, four mild, seven osteitis
fibrosa, one mixed, and two osteomalacic. They did not alter
the distribution of the various lesions. None of the patients had
excess marrow iron and none had iron on trabecular bone
surfaces.
There were few differences in the various bone lesions seen
which related to the type of dialysis treatment. The only
statistically significant differences, shown in Table 4, were that
bone surface aluminum levels were higher in the HD population
than in the PD population. Assessing individual subgroups
revealed that mixed, aplastic and possibly mild patients on HD
had higher surface bone aluminum than their peers on PD,
Although mean values in the osteomalacic patients treated in
these two different ways differed markedly, the difference was
not significant, probably because of the small numbers in-
volved. Patients with osteitis fibrosa had the same surface
aluminum whether they were treated with PD or HD.
Table 5 shows the distribution of bone disease with respect to
three different levels of bone surface aluminum accumulation.
Only osteomalacia was seen with increased frequency with high
aluminum levels. Osteitis fibrosa, on the other hand, seemed to
Table 5. Bone disease at different bone aluminum levels (bone
surface aluminum)
Bone surface
aluminum 0-5% 6-25% >25%
N 94 80 85
Mild 18 (19) 12 (15) 15 (18)
Osteitis 19 (20) 24 (30) 14 (17)
fibrosa
Mixed 7 (7) 5 (6) 6 (7)
Osteomalaciaa 1 (1) 0 10 (12)
Aplastic 49 (53) 39 (49) 40 (47)
a P < 0.0005; osteomalacia differs from all other groups (Fisher's
exact test). Figures in parentheses are percentages.
be somewhat less common in patients with the highest levels of
aluminum accumulation. The aplastic lesion was seen with
equal frequency at all levels of bone surface aluminum accu-
mulation. To evaluate this point further we looked at the 44
patients (17% of the total population) whose bones were abso-
lutely negative by the aluminon stain; 22 (50%) had the aplastic
lesion and 13 (30%) had osteitis fibrosa, essentially the same
percentages as in patients with the highest levels of aluminum.
It is evident that there are substantial differences in the
distribution of the different bone lesions with the different
treatments (Fig. 1). Low turnover lesions (osteomalacia and the
aplastic form of ROD), in particular the aplastic disorder, are
more common with PD. High turnover lesions (mixed, osteitis),
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Peritoneal dialysis Hemodialysis
Fig. 1. Distribution of bone lesions in
peritoneal dialysis and hemodialysis patients.
Numbers within the figures are the numbers
of patients in each group of bone disorders.
Abbreviations are: O.F., osteitis fibrosa; Mx,
mixed uremic osteodystrophy; OM,
osteomalacia.
Table 6. Parathyroid hormone levels in renal osteodystrophy
Peritoneal dialysis Hemodialysis Total
NN N
Mild 30 15.30 1.53 15 17.22 3.12 45 15.94 1.48
Osteitis 13 41.11 7.06 44 55.11 7.14 57 51.92 5.69a
Mixed 5 32.68 5.03 13 41.57 5,83 18 39.1 45b
Osteomalacia 8 8.30 0.85 3 4.27 6.65 11 7.20 0.92
Aplastic 86 7.75 0.70 42 7.57 0.83 128 7.69 0.54
Total 142 13.3 1.2 117 30 3,4C 259 20.0 1.6
Normal parathyroid hormone levels range from 1—5.5 p. Statistics are based on log transformed data.
a Mild greater than aplastic (P < 0.01)
b Osteitis greater than mild, osteomalacia, aplastic (P < 0.0001)
Mixed greater than mild, osteomalacia, aplastic (P < 0.01) (Tukey) (P < 0.0001)
d Hemodialysis greater than peritoneal dialysis (P < 0.0005)
Table 7. Random serum aluminum in renal osteodystrophy
Histologic
Peritoneal dialysis Hemodialysis
groups N N
All patients
N
Mild 30 879 148 15 1725 350k 45 1161 163
Osteitis fibrosa 13 1591 359 44 1636 196 57 1626 156
Mixed 5 260 56 13 2358 539 18 1775 442
Osteomalacia 8 3187 1527 3 4640 2479b 11 3583 1242
Aplastic 86 932 102 42 2340 314C 128 1394 137
Total 142 1084 119 117 2057 1787 259 1524 104
Serum aluminum in nM; 100 nM = 2.7 jsglliter. Statistical tests are based on log transformed data.
a P < 0.05 versus pentoneal dialysisb P < 0.0005 versus peritoneal dialysisP < 0.002 versus peritoneal dialysis
in particular osteitis fibrosa, are more common with HD. The
mild lesion, with normal bone formation, is slightly more
common in the PD group, but this difference is not significant.
Tables 6 and 7 and Figure 2 depict the relationship of serum
PTH, random serum aluminum and DFO-stimulated aluminum
levels to the bone lesions. PTH is clearly much higher in the
high turnover lesions (osteitis fibrosa and mixed uremic os-
teodystrophy), intermediate in the mild lesion with normal bone
formation and lowest in the two low turnover lesions, osteoma-
lacia and aplastic disease. In all of these groups, the mean PTH
level was well above normal. Within each bone lesion PTH
levels were not affected by dialysis modality, though PTH
levels were higher overall in HD than PD.
Random and stimulated serum aluminum levels tended to be
the converse of the PTH levels, with the lowest levels in the
high turnover lesions and the highest levels in the low turnover
groups. Only the osteomalacic group, however, differed signif-
icantly from other histologic groups. Strikingly, both mean
random and stimulated serum aluminum levels were higher in
HD than in PD. For both random and stimulated serum alumi-
num this achieved significance in aplastic, mixed, and mild
subgroups. Osteomalacic patients appeared to have higher
440 Sherrard et a!: Current status of renal osteodystrophy
aplastic patients were identified at that time; presumably those
patients were infrequent. Ellis et a! [16] reported on bone
biopsies from 276 dialysis patients in 1977. The majority were
said to have mixed uremic osteodystrophy, while pure osteitis
fibrosa occurred in approximately one-third. A smaller number
* * were said to have osteomalacia, but precise numbers are not
H H given for any of these categories nor are specific diagnostic
criteria. There was no mention of the histologically less severe
lesions (that is, mild and aplastic) that we have described. In
1982 we described the association between aluminum and
osteomalacia [17] and commented for the first time on the
• p "aplastic" lesion, although we did not clearly differentiate itP from the mild lesion at the time. More recently Smith et a! [18]
_______________
reported their findings in 97 dialysis patients; 16% had low
Aplastic turnover/osteomalacia, 13% had hyperparathyroid bone disease
Total and 71% had mixed uremic osteodystrophy. Because precise
criteria for these categories were also not given it is difficult to
know how these prior studies compare with our current data.
Liach's report [191 of 142 unselected patients in 1986 described
a 7% incidence of aplastic bone disease, a 25% incidence of
osteomalacia, and a 68% incidence of osteitis fibrosa. They
combined mixed uremic osteodystrophy with osteitis fibrosa in
their analysis. They also noted that osteomalacia and aplastic
bone disease were associated with lower serum PTH, higher
serum aluminum levels and higher bone surface aluminum
levels than osteitis fibrosa. Thus, all prior reports note a high
incidence of osteitis fibrosa and osteomalacia. Only Liach's
report gives a figure for the prevalence of the aplastic disorder
and this is much lower than the current study. If the aplastic
lesion had occurred with anything approaching the frequency in
our study, it would most likely have been identified. Since the
definitions for osteomalacia and osteitis fibrosa have not
changed over the past 20 years and the aplastic lesion was not
identified, it seems probable that there has been a real change in
the histology of renal osteodystrophy.
The distribution of bone lesions in the present study appears
to differ in two ways from previous reports. First, patients with
osteomalacic lesions are much less common (4%). Largely due
to aluminum [17, 18], this lesion has become less frequent as the
use of aluminum hydroxide declines. Second, the aplastic [2]
lesion (a low turnover lesion without an increase in osteoid
area) is the most common histopathology seen. Curiously, it is
seen at all levels of aluminum accumulation, suggesting that
either aluminum has little to do with causing this disorder or
that it results from multiple causes. Since a large body of
convincing data support the thesis that aluminum is toxic to
bone and aluminum chelation [20] results in both the disappear-
ance of aluminum and normalization of bone formation, it
seems clear that this is one cause of low turnover bone disease
in renal failure.
On the other hand we have found a high incidence of the
aplastic disorder even in patients who had no aluminum by the
histochemical staining method we used. One could argue that a
more sensitive method [21] might detect aluminum even in
these patients. This is possible, but low serum aluminum both
before and after DFO stimulation in these subjects [3] suggest
that their aluminum stores were little, if at all, increased.
Furthermore, in a previous preliminary report [22] on the first
175 patients in this study we noted that the bone aluminum in an
ashed sample measured by atomic absorption in 29 of these
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Fig. 2. Serum aluminum response to deferoxamine. Shown are mean
standard error. Asterisks indicate a signifIcant difference between
hemodialysis and peritoneal dialysis patients in the different groups.
aluminum levels on HD, but numbers were too small to achieve
significance.
Because of these observations we assessed the relationship of
PTH, random serum aluminum, and stimulated serum alumi-
num to bone formation rate in the total population. Intact-PTH
correlated directly with bone formation rate (r = 0.696, P <
0.0001). After accounting for the relationship between bone
formation and PTH, neither random serum aluminum nor
deferoxamine stimulated aluminum showed a relationship with
bone formation.
Discussion
Since the onset of dialysis treatment the regimen has been in
constant flux. In the past decade major changes have included
the large scale introduction of peritoneal dialysis and the
inclusion of many aged and diabetic subjects in dialysis pro-
grams. Calcitriol, the active form of vitamin D, has also been
introduced and is widely used. Awareness of aluminum toxicity
as a serious problem in patients with chronic failure led clini-
cians to control serum phosphate with calcium compounds
instead of aluminum salts. Therefore, many of these patients
were in transition (as was/is the dialysis community in general),
therapeutically. Doses of related drugs, such as vitamin D, were
also adjusted as other therapy changed. The results we report
must be considered, then, in the context of this transitional
environment.
Also our study differs from those previously published be-
cause of the large numbers of both symptomatic and asymp-
tomatic patients who were included. Most previous reports are
of small numbers of subjects who were often selected for study
because they were symptomatic, hypercalcemic or presented
some clinical, radiologic, or laboratory problem. As a result,
our comments about changes in prevalence, distribution or
other features must be somewhat qualified.
In 1972 we reported on the distribution of bone lesions in 67
chronic HD patients [15]; 16 (24%) had osteomalacia, 15 (22%)
had osteitis fibrosa, six (9%) had mixed uremic osteodystrophy,
and the remaining 30 patients (45%) had the mild lesion. No
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aplastic subjects with surface stainable aluminum 5% was
12.8 4.3, a value little different from normal, but quite
different from the 21 aplastic subjects with high bone surface
aluminum who had ash aluminum levels of 55.8 10.9 mg/kg
dry weight. Both we and Malluche [23, 24] have previously
noted that stainable aluminum was more sensitive than total
bone aluminum in identifying toxicity. Others [25] have com-
mented that the aluminum localized to the bone surface corre-
lates better with evidence of osteoblast toxicity than aluminum
at other sites. Finally, in two previous studies [17, 26] we have
reported that the stain correlates strongly with total bone
aluminum. Thus, it seems likely that the aluminon stain accu-
rately defines aluminum toxicity.
This information raises questions about the pathophysiology
of aluminum bone disease. Previously we have characterized
aluminum bone disease [7] as having high bone surface alumi-
num (>25%) and depressed bone formation (<108 m2/mm2 of
bone area/day). While others have suggested that any amount of
aluminum is toxic [27], we have shown that bone formation is
usually normal when bone surface aluminum is <25% [28]. Still
others have used the absolute amount of aluminum on bone
surfaces (usually 25% or 30% of cancellous bone) as the
definition of aluminum toxicity [29]. One group has questioned
whether aluminum accumulation is anything more than an
epiphenomenon [30]. The present study does seem to clarify
this controversy to some extent. The association of osteomala-
cia with aluminum toxicity is apparently validated. The other
low turnover lesion, which we have termed the aplastic disorder
[17], is just as likely to be seen in the absence of aluminum as in
the presence of large amounts. Thus, it would appear that the
only way to be certain whether this lesion results from alumi-
num is to remove the aluminum and see if it improves. Cer-
tainly, in many cases, as noted, this does occur [20].
There are several other possibilities that might explain the
findings in these patients. Iron, for example, has been reported
to have bone toxicity similar to aluminum [31]. As noted,
however, none of our patients had evidence of excessive iron.
Parathyroidectomy can also result in low bone turnover. With
only 10 previously parathyroidectomized subjects, and these
distributed across all groups, this does not explain our findings.
Excessive parathyroid suppression with calcitriol might also
lead to this appearance. The relatively low dose of calcitriol
used in only 12% of the population, distributed across all groups
and types of treatment, excludes this therapy as an important
contributor to our findings.
Another question this study addresses is whether the mode of
dialysis influences the pattern of ROD. Clearly, this does
appear to be the case, with a preponderance of low turnover
lesions in PD, while high turnover lesions are more typical of
HD treatment. The mechanisms for these differences may relate
to the more sustained and higher calcium level associated with
CAPD [32] which probably results in more effective PTH
suppression than the intermittent calcium loading of HD. A
lower PTH, then, may lead to a shift in the bone pathology
away from high turnover (probably PTH dependent) lesions to
low turnover bone disorders. The exact relationship of PTH to
the bone lesions will need to be defined in a prospective study.
Thus, such an explanation is plausible but not proven by our
data.
Though we did not measure vitamin D levels in these subjects
others have pointed out that vitamin D metabolites (including 25
hydroxy-, 1,25 dihydroxy-, and 24,25 dihydroxy-vitamin D) are
lower in PD than HD patients. This is presumably due to loss of
these substances along with vitamin D binding protein in PD
fluid [33]. It is unclear whether any adverse effects result from
these deficits, particularly if calcium levels are maintained. One
might expect that a lower level of 1,25 dihydroxy-vitamin D
would lead to a higher PTH level in the PD patients, the reverse
of what we actually observed.
A number of the demographic factors noted in Table 1 could
relate to the increased prevalence of the aplastic lesion in PD
patients. In particular, the older age, increased use of calcium
carbonate and increased incidence of diabetes [341 might play a
role.
The effects of PTH on bone in uremic stibjects remain
controversial. PTH resistance has been described and thought
to be in part a result of calcitriol deficiency [35]. While we have
not directly addressed whether PTH resistance is present in
these subjects, it is noteworthy that bone formation rate ap-
pears to be PTH dependent. This relationship is curious,
however, in that even with very low levels of bone formation
PTH is substantially elevated. Thus, one wonders if bone
formation in uremic patients "requires" a higher level of PTH
than in normal subjects. Whether this "requirement" could be
met by calcitriol is not clear, but in prior studies of PTH
suppression using calcitriol we have found that many patients
have normal bone formation in the presence of persistent PTH
elevation [36—38]. Therefore, calcitriol alone does not seem to
affect PTH resistance. One has to assume that there are
deficiencies in other trophic factors, excesses of growth inhib-
itors in uremic subjects, or possibly receptor or post-receptor
events in uremia that lead to this resistance.
While the current division of renal osteodystrophy into
several distinct types is somewhat arbitrary, the original cate-
gories were arrived at by cluster analysis [4]. There does not
appear to be any good reason to alter these now well-accepted
categories. Since that original description there has been an
evolution of the disease as well as our understanding of it. Both
osteitis fibrosa and mixed uremic osteodystrophy appear to be
mediated by PTH. The differences in their appearance may be
due to other factors than PTH alone (such as the level of
calcium, phosphate or vitamin D), but the treatment should
focus on the medical or, if necessary, surgical correction of
hyperparathyroidism. Osteomalacia, usually due to aluminum,
appears to have an equally straightforward management—the
avoidance or removal of aluminum. The mild lesion occurs
early in the course of renal disease, usually is asymptomatic,
and requires only calcium maintenance and phosphate control.
Only the aplastic lesion remains a therapeutic and etiologic
enigma. Certainly due to aluminum in some cases, management
in those cases should be similar to osteomalacia. In other cases
the cause is less obvious and the treatment unclear. In the
absence of aluminum this lesion, indeed, may not be particu-
larly dysfunctional, but merely the bone response to aggressive
PTH control. Usually such patients are asymptomatic. Until
more is known about the consequent morbidity, if any, of this
condition, it seems unwise to be in a hurry to fix it. The major
difficulty such patients encounter is a predisposition to hyper-
calcemia. This can be managed by a reduction in oral calcium
442 Sherrard et al: Current status of renal osteodystrophy
intake or dialysate calcium levels. At this time, nothing more is
indicated.
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